表紙
市場調査レポート

炎症性腸疾患(IBD)の治療・バイオマーカー

Therapies and Biomarkers for Inflammatory Bowel Disease

発行 BCC Research 商品コード 258271
出版日 ページ情報 英文 115 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
炎症性腸疾患(IBD)の治療・バイオマーカー Therapies and Biomarkers for Inflammatory Bowel Disease
出版日: 2013年01月01日 ページ情報: 英文 115 Pages
概要

当レポートでは、炎症性腸疾患(IBD)の治療・バイオマーカー市場の現状と見通しについて調査分析し、世界市場の動向、予測および今後5年間のCAGR予測、IBDタイプ別(クローン病、潰瘍性腸疾患など)、診断法(便培養、血液検査、大腸内視鏡検査、内視鏡検査、放射線など)および治療法(疾患管理向け臨床ガイドライン、治療薬、手術など)別の分析、研究開発動向、産業構造、主な競合要因、および主要企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 炎症性腸疾患

第4章 炎症性腸疾患の生理学

  • 概要

第5章 炎症性腸疾患製品のセグメント

  • 炎症性腸疾患向け非生物製剤
  • 炎症性腸疾患向け生物製剤
  • 炎症性腸疾患治療の世界市場
  • 炎症性腸疾患治療の新しい治療法

第6章 炎症性腸疾患の研究開発

  • 炎症性腸疾患管理の臨床ガイドライン
  • 炎症性腸疾患の現在の治療法

第7章 炎症性腸疾患向けバイオマーカー

  • 炎症性腸疾患バイオマーカー

第8章 特許情勢

  • 炎症性腸疾患診断・治療産業

第9章 企業プロファイル

  • 炎症性腸疾患診断分野の企業
  • 炎症性腸疾患治療分野の企業
  • M&A:診断
  • M&A:治療

第10章 市場要因

  • 強み・弱み・機械・脅威

第11章 付録

図表

目次
Product Code: PHM125A

Abstract

REPORT HIGHLIGHTS

This report provides:

An overview of the global market for therapies and biomarkers for inflammatory bowel disease (IBD)

Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017

Discussion of the types of IBD, including Crohn's disease, ulcerative colitis, and other (ischemic, diversionary, Bechet's)

Examination of the types of IBD diagnostics, such as stool cultures, blood tests, and colonoscopy, endoscopy and radiology; and therapies, such as clinical guidelines for managing the disease, drugs, and surgery

A breakdown of research and development, the current drugs approved for treatment, and current clinical trials of drugs

Industry structure, key competitive factors, and growth drivers and obstacles

Comprehensive company profiles of key players.

image1

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research report, Therapies and Biomarkers for Inflammatory Bowel Disease, provides a detailed analysis of the products and technologies that define the market space and summarizes the composition and dynamics of individual companies in the competitive environment. The study also includes an overview of the relevant regulatory issues, patent landscapes and strategic partnerships that will play substantial roles in shaping the market in the future.

REASONS FOR DOING THE STUDY

Inflammatory bowel diseases (IBDs), notably Crohn's disease (CD) and ulcerative colitis (UC), are estimated to affect more than four million people globally. The precise etiology of these diseases is under active investigation, but the clinical observation that many IBD patients respond to anti-inflammatory medications with concomitant U.S. Food and Drug Administration (FDA) approval for alternative indications (e.g., infliximab [Remicade], a chimeric IgG1k monoclonal antibody targeted against TNF-alpha) makes IBD a disease class with broad market appeal to the pharmaceutical and biotechnology industries. In addition, the clinical removal of biopsy samples from IBD patients is a routine part of the standard of care in many cases, and thus the widespread availability of tissue samples from the site of active disease makes IBD a disease class in which the potential for disease and therapeutic biomarker discovery has a practical basis. Clinical biomarkers, whether used to assess IBD disease severity or to inform treatment regimens, represent a significant market segment in IBD management.

Despite the existence of diagnostics and therapeutics for IBD, the pharmaceutical, medical and payor market sectors are keeping up the demand for the development of better technologies. With the upcoming patent expiry of the biologic drug Remicade, the most efficacious treatment for Crohn's and UC, the recent approval of several other biologic therapies for IBD, along with a shift in the clinical setting to toward treating with biologic therapies earlier in the course of disease, the market for IBD therapeutics is in a state of heavy flux.

SCOPE OF REPORT

The study scope of this report includes commercialized products used in the diagnosis and treatment of IBD, as well as novel products and technologies that may be commercially viable by 2017. Important IBD disease mechanisms, technologies for biomarker discovery, industry structure, and key players and factors influencing demand for IBD therapeutics are discussed. Suppliers of IBD diagnostic and therapeutic products are discussed, with the market for IBD therapeutics analyzed based on product types and regions. In addition to an in-depth analysis of the intellectual property landscape for major industry players, this report highlights recent industrial shifts (e.g., strategic alliances, mergers and acquisitions, major venture capital deals) in the IBD diagnostic and therapeutic space. Forecasted market growth from 2012 through 2017 is presented.

In addition to examining larger and more-established producers in IBD diagnostic and therapeutic product market segments, BCC Research profiled numerous smaller specialized market players in this report. Market segmentation within the areas of therapeutic class and geographical areas are highlighted. Each technology is analyzed by application type and in the context of relevant technological and regulatory forces to determine its current market status and forecasted growth through 2017. Recent industrial alliances and acquisitions affecting producer market penetration and dominance are also discussed.

Topics that are specifically excludedfrom this study, as they are considered beyond the scope of this report, include a detailed market analysis for IBD diagnostic procedures (e.g., colonoscopy, endoscopy, radiology) and IBD classes with lower incidence and prevalence rates (e.g., ischemic, diversionary, Bechet's). A detailed market analysis for products used for the palliative care of IBD and non-laboratory diagnostics for IBD detection were also excluded from this study.

INTENDED AUDIENCE

This report will be of general interest to business professionals in the pharmaceutical, biotechnology and investment fields. Both producers and consumers of IBD diagnostics and therapeutics will benefit from the comprehensive summary of relevant technologies and industrial profiles contained within this study. Consultants, strategic and market analysts, and investors working within the pharmaceutical, clinical and biotechnology industries will also find this report particularly useful. In addition, business development professionals, as well as those in sales, marketing, information sciences and competitive intelligence fields of biotechnology, will benefit from the information contained in this report.

METHODOLOGY AND INFORMATION SOURCES

The market assessments presented in this report were derived from publicly available information up to and including September 2012 in conjunction with primary source interviews. Using 2010 as the base year, forecast data are provided through 2017. In cases where data for 2012 were incomplete or not readily available, figures were extrapolated from 2011 statistics, half-year figures for 2012 and historical trends between 2010 and 2012. Market figures are based on current U.S. dollars with no adjustments for inflation made in the projections.

The information contained in this report has been assembled from both primary and secondary data sources. Primary research was conducted via telephone or e-mail correspondence with industry professionals, research scientists, physicians, researchers and laboratory heads to discover the most recent developments in their fields of interest. Secondary data were collected via a comprehensive search of the scientific, peer-reviewed literature; clinical trial reports and databases; industry trade media; company websites; annual reports; intellectual-property databases; and industry press releases.

ANALYST CREDENTIALS

Dr. Willem Westra brings more than a decade of experience as an analyst in diverse areas of biomedical science, including basic research, intellectual property and investor relations, to BCC Research. He is the author of several peer-reviewed scientific articles and book chapters, and he actively works with major domestic and international pharmaceutical and biotechnology companies to evaluate potential biomarkers for autoimmune diseases. In addition to his pharmaceutical industry experience, Dr. Westra has served as an intellectual property/patent consultant, held visiting faculty positions in academia and has worked as a professional ski instructor. Dr. Westra has earned both a B.S. in Pharmacological Chemistry and a Ph.D. in Biomedical Science from the University of California, San Diego.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

Chapter- 2: SUMMARY

  • Table Summary : GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, THROUGH 2017
  • Figure Summary : GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, BY REGION, 2010-2017

Chapter- 3: OVERVIEW

  • INFLAMMATORY BOWEL DISEASE

Chapter- 4: INFLAMMATORY BOWEL DISEASE PHYSIOLOGY

  • OVERVIEW

Chapter- 5: INFLAMMATORY BOWEL DISEASE PRODUCT SEGMENTS

  • NON-BIOLOGIC DRUGS FOR INFLAMMATORY BOWEL DISEASE
  • BIOLOGIC DRUGS FOR INFLAMMATORY BOWEL DISEASE
  • GLOBAL MARKETS FOR INFLAMMATORY BOWEL DISEASE THERAPEUTICS
  • EMERGING THERAPIES FOR INFLAMMATORY BOWEL DISEASE
  • Table 21 : INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET SEGMENTATION

Chapter- 6: INFLAMMATORY BOWEL DISEASE RESEARCH AND DEVELOPMENT

  • CLINICAL GUIDELINES FOR MANAGING INFLAMMATORY BOWEL DISEASE
  • CURRENT THERAPIES FOR INFLAMMATORY BOWEL DISEASE

Chapter- 7: BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE

  • INFLAMMATORY BOWEL DISEASE BIOMARKERS
  • Table 45 : PUBMED-INDEXED SCIENTIFIC PUBLICATIONS FOR INFLAMMATORY BOWEL DISEASE BIOMARKERS, 2002-2012

Chapter- 8: PATENT LANDSCAPE

  • INFLAMMATORY BOWEL DISEASE DIAGNOSTICS AND THERAPEUTICS INDUSTRY

Chapter- 9: COMPANY PROFILES

  • COMPANIES IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTICS SPACE
  • COMPANIES IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTICS SPACE
  • MERGERS AND ACQUISITIONS: DIAGNOSTICS
  • MERGERS AND ACQUISITIONS: THERAPEUTICS

Chapter- 10: MARKET FACTORS

  • STRENGTH, WEAKNESS, OPPORTUNITY AND THREAT ANALYSIS

Chapter- 11: APPENDIX DEFINITIONS

  • ANTIBODY
  • AUTOIMMUNE DISEASE
  • BIOLOGIC THERAPY
  • BOWEL
  • COMPANION DIAGNOSTIC
  • CLINICAL LABORATORY IMPROVEMENT AMENDMENT
  • CROHN'S DISEASE
  • CURRENT PROCEDURAL TERMINOLOGY
  • DIAGNOSTIC SENSITIVITY
  • DIAGNOSTIC SPECIFICITY
  • ILEUM
  • INCIDENCE
  • INFLAMMATORY BOWEL DISEASE
  • MICROBIOTA AND MICROBIOME
  • NUCLEOTIDE
  • PREVALENCE
  • SEROLOGY
  • SINGLE-NUCLEOTIDE POLYMORPHISM
  • TUMOR NECROSIS FACTOR ALPHA
  • ULCERATIVE COLITIS

List of Tables

  • Summary Table : GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, THROUGH 2017
  • Table 1 : GLOBAL INCIDENCE RANGES FOR CROHN'S DISEASE AND ULCERATIVE COLITIS
  • Table 2 : GLOBAL PREVALENCE OF CROHN'S DISEASE AND ULCERATIVE COLITIS
  • Table 3 : GLOBAL INCIDENCE FOR CROHN'S DISEASE
  • Table 4 : GLOBAL PREVALENCE FOR CROHN'S DISEASE
  • Table 5 : GLOBAL INCIDENCE FOR ULCERATIVE COLITIS
  • Table 6 : GLOBAL PREVALENCE FOR ULCERATIVE COLITIS
  • Table 7 : THERAPEUTIC OPTIONS FOR INFLAMMATORY BOWEL DISEASE
  • Table 8 : DIAGNOSTIC BIOMARKER EXAMPLES
  • Table 9 : PREDICTIVE BIOMARKER EXAMPLES
  • Table 10 : BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE
  • Table 11 : PUBMED-INDEXED SCIENTIFIC PUBLICATIONS REGARDING INFLAMMATORY BOWEL DISEASE BIOMARKERS, 2002-2012
  • Table 12 : OPEN CLINICAL TRIALS FOR CROHN'S DISEASE THERAPEUTICS BY LOCATION, 2012
  • Table 13 : OPEN CLINICAL TRIALS FOR ULCERATIVE COLITIS THERAPEUTICS BY LOCATION, 2012
  • Table 14 : CLINICAL ASPECTS OF INFLAMMATORY BOWEL DISEASE SUBTYPES
  • Table 15 : FACTORS FOR CALCULATING THE CROHN'S DISEASE ACTIVITY INDEX SCORE
  • Table 16 : FACTORS FOR CALCULATING THE HARVEY - BRADSHAW INDEX
  • Table 17 : FACTORS FOR CALCULATING THE MAYO SCORE
  • Table 18 : INFLAMMATORY BOWEL DISEASE SEROLOGIES TO INFORM CLINICAL DIAGNOSES
  • Table 19 : GENETIC LOCI IMPLICATED IN INFLAMMATORY BOWEL DISEASE
  • Table 20 : ENVIRONMENTAL RISK FACTORS FOR INFLAMMATORY BOWEL DISEASE
  • Table 21 : INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET SEGMENTATION
  • Table 22 : COMPETITOR ASSESSMENT OF THE MAJOR MARKETED INFLAMMATORY BOWEL DISEASE THERAPEUTICS, 2012
  • Table 23 : GLOBAL REVENUE FOR INFLAMMATORY BOWEL DISEASE-SPECIFIC NON-BIOLOGIC DRUGS, THROUGH 2017
  • Table 24 : GLOBAL MARKET SHARES FOR INFLAMMATORY BOWEL DISEASE-SPECIFIC NON-BIOLOGIC DRUGS, 2011
  • Table 25 : GLOBAL REVENUE FOR INFLAMMATORY BOWEL DISEASE BIOLOGIC DRUGS, THROUGH 2017
  • Table 26 : GLOBAL MARKET SHARE FOR INFLAMMATORY BOWEL DISEASE-SPECIFIC BIOLOGIC DRUGS, 2011
  • Table 27 : LEADING INTERNATIONAL MARKETS FOR INFLAMMATORY BOWEL DISEASE THERAPEUTICS, THROUGH 2017
  • Table 28 : U.S. MARKET FOR INFLAMMATORY BOWEL DISEASE DRUGS, THROUGH 2017
  • Table 29 : JAPANESE INFLAMMATORY BOWEL DISEASE DRUG MARKET, THROUGH 2017
  • Table 30 : EU5 INFLAMMATORY BOWEL DISEASE DRUG MARKET, THROUGH 2017
  • Table 31 : REST OF THE WORLD INFLAMMATORY BOWEL DISEASE DRUG MARKET, THROUGH 2017
  • Table 32 : THERAPEUTIC PIPELINE FOR CROHN'S DISEASE THERAPIES
  • Table 33 : CLINICAL TRIAL RESULTS FOR EMERGING THERAPIES FOR CROHN'S DISEASE
  • Table 34 : THERAPEUTIC PIPELINE FOR ULCERATIVE COLITIS THERAPIES
  • Table 35 : CLINICAL TRIAL RESULTS FOR EMERGING ULCERATIVE COLITIS THERAPIES, 2007-2012
  • Table 36 : THERAPIES FOR INFLAMMATORY BOWEL DISEASE
  • Table 37 : ANTI-DIARRHEAL THERAPIES FOR INFLAMMATORY BOWEL DISEASE
  • Table 38 : ANTIBIOTIC THERAPIES FOR INFLAMMATORY BOWEL DISEASE
  • Table 39 : AMINOSALICYLATE THERAPIES FOR INFLAMMATORY BOWEL DISEASE
  • Table 40 : CORTICOSTEROID THERAPIES FOR INFLAMMATORY BOWEL DISEASE
  • Table 41 : IMMUNOSUPPRESSANT THERAPIES FOR INFLAMMATORY BOWEL DISEASE
  • Table 42 : BIOLOGIC THERAPIES FOR INFLAMMATORY BOWEL DISEASE
  • Table 43 : OPEN CLINICAL TRIALS FOR CROHN'S DISEASE THERAPEUTICS BY LOCATION, 2012
  • Table 44 : OPEN CLINICAL TRIALS FOR ULCERATIVE COLITIS THERAPEUTICS BY LOCATION, 2012
  • Table 45 : PUBMED-INDEXED SCIENTIFIC PUBLICATIONS FOR INFLAMMATORY BOWEL DISEASE BIOMARKERS, 2002-2012
  • Table 46 : SERUM INFLAMMATORY BOWEL DISEASE BIOMARKERS
  • Table 47 : FECAL INFLAMMATORY BOWEL DISEASE BIOMARKERS
  • Table 48 : NOVEL INFLAMMATORY BOWEL DISEASE BIOMARKERS
  • Table 49 : MAJOR PATENT HOLDERS IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTICS SPACE
  • Table 50 : PUBLISHED PATENTS FOR PROMETHUES LABORATORIES IN INFLAMMATORY BOWEL DISEASE, 2005 - 2012
  • Table 51 : PUBLISHED PATENTS FOR EXAGEN DIAGNOSTICS IN INFLAMMATORY BOWEL DISEASE, 2005 - 2012
  • Table 52 : MAJOR PATENT HOLDERS IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTICS SPACE
  • Table 53 : PUBLISHED PATENTS FOR PFIZER IN INFLAMMATORY BOWEL DISEASE, 2005 - 2012
  • Table 54 : PUBLISHED PATENTS FOR NOVARTIS IN INFLAMMATORY BOWEL DISEASE, 2005 - 2012
  • Table 55 : PUBLISHED PATENTS FOR NOVARTIS IN INFLAMMATORY BOWEL DISEASE, 2005 - 2012
  • Table 56 : INFLAMMATORY BOWEL DISEASE DIAGNOSTIC COMPANIES
  • Table 57 : INFLAMMATORY BOWEL DISEASE DIAGNOSTIC COMPANIES BY REVENUE PER EMPLOYEE, 2011
  • Table 58 : INFLAMMATORY BOWEL DISEASE THERAPEUTIC COMPANIES
  • Table 59 : INFLAMMATORY BOWEL DISEASE DIAGNOSTIC COMPANIES BY REVENUE PER EMPLOYEE, 2011
  • Table 60 : SIGNIFICANT MERGERS AND ACQUISITIONS IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTIC MARKET, 2008 - 2012
  • Table 61 : SIGNIFICANT VENTURE-CAPITAL DEALS IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTIC MARKET, 2004 - 2012
  • Table 62 : SIGNIFICANT STRATEGIC ALLIANCES IN THE INFLAMMATORY BOWEL DISEASE DIAGNOSTIC MARKET, 2008 - 2012
  • Table 63 : SIGNIFICANT MERGERS AND ACQUISITIONS IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, 2008 - 2012
  • Table 64 : SIGNIFICANT VENTURE-CAPITAL DEALS IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, 2008 - 2012
  • Table 65 : SIGNIFICANT STRATEGIC ALLIANCES IN THE INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, 2008-2012
  • Table 66 : STRENGTH, WEAKNESS, OPPORTUNITY AND THREAT ANALYSIS FOR THE GLOBAL INFLAMMATORY BOWEL DISEASE MARKET

List of Figures

  • Summary Figure : GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTIC MARKET, BY REGION, 2010-2017
Back to Top